Gender differences characterize amyotrophic lateral sclerosis (ALS). Since ALS patients have increased circulating levels of transforming growth factor beta 1 (TGFB1), here we analysed gender and disease progression related modification of TGFB1 and its related signaling molecules in spinal cord and skeletal muscle of ALS mice and in muscle biopsies from sporadic ALS patients. At presymptomatic (PS) stage Tgfb1 expression is reduced in mouse spinal cord, but is increased selectively in male skeletal muscle. At symptomatic (S) stage Tgfb1 is induced both in mouse spinal cord and muscle, as well as in muscle of ALS patients. Tgfbr2 levels are induced only in mouse spinal cord. Smad2 and Smad4 are decreased in mouse spinal cord and muscle, but SMAD2 protein levels are augmented selectively in male mouse muscle. Smad3 mRNA and SMAD3 protein are increased in mouse muscle. Genes controlled by TGFB1 in muscle (Pax7, Collagen1a1 and Fibronectin) are reduced both in male and female ALS mice at S stage. Thus, TGFB1 modulation may serve as a novel therapeutic target for ALS.

Transforming Growth Factor beta 1 signaling is altered in the spinal cord and muscle of amyotrophic lateral sclerosis mice and patients / M. Meroni, V. Crippa, R.M. Cristofani, P. Rusmini, M.E. Cicardi, E. Messi, M. Piccolella, B. Tedesco, V. Ferrari, G. Sorarù, M. Pennuto, A. Poletti, M. Galbiati. - In: NEUROBIOLOGY OF AGING. - ISSN 0197-4580. - 82(2019 Oct), pp. 48-59. [10.1016/j.neurobiolaging.2019.07.001]

Transforming Growth Factor beta 1 signaling is altered in the spinal cord and muscle of amyotrophic lateral sclerosis mice and patients

M. Meroni;V. Crippa;R.M. Cristofani;P. Rusmini;M.E. Cicardi;E. Messi;M. Piccolella;B. Tedesco;V. Ferrari;A. Poletti
;
M. Galbiati
2019

Abstract

Gender differences characterize amyotrophic lateral sclerosis (ALS). Since ALS patients have increased circulating levels of transforming growth factor beta 1 (TGFB1), here we analysed gender and disease progression related modification of TGFB1 and its related signaling molecules in spinal cord and skeletal muscle of ALS mice and in muscle biopsies from sporadic ALS patients. At presymptomatic (PS) stage Tgfb1 expression is reduced in mouse spinal cord, but is increased selectively in male skeletal muscle. At symptomatic (S) stage Tgfb1 is induced both in mouse spinal cord and muscle, as well as in muscle of ALS patients. Tgfbr2 levels are induced only in mouse spinal cord. Smad2 and Smad4 are decreased in mouse spinal cord and muscle, but SMAD2 protein levels are augmented selectively in male mouse muscle. Smad3 mRNA and SMAD3 protein are increased in mouse muscle. Genes controlled by TGFB1 in muscle (Pax7, Collagen1a1 and Fibronectin) are reduced both in male and female ALS mice at S stage. Thus, TGFB1 modulation may serve as a novel therapeutic target for ALS.
ALS; muscle; spinal cord; TGFB1; SMAD; Pax7; Col1a1; fibronectin
Settore BIO/13 - Biologia Applicata
Settore BIO/09 - Fisiologia
   Translating molecular mechanisms into ALS risk and patient's well-being
   TRANS-ALS
   FONDAZIONE REGIONALE PER LA RICERCA BIOMEDICA
   2015-0023

   RAN translation of normal and expanded nucleotide repeat containing transcripts to neurotoxic polypetides in neurodegenerative diseases
   No RAn for old man
   FONDAZIONE CARIPLO
   2014-0686

   Stress granules and proteostasis in motor neurons: towards a mechanistic understanding of ALS (CureALS)
   CureALS
   MINISTERO DELL'ISTRUZIONE E DEL MERITO

   From RNA to Protein toxicity in motorneuron diseases
   MINISTERO DELL'ISTRUZIONE E DEL MERITO
   2015LFPNMN_006

   The interplay between the “rna/protein quality control system” and “exosomes” as a spreading mechanism in amyotrophic lateral sclerosis (EX_ALS)
   EX_ALS
   MINISTERO DELL'ISTRUZIONE E DEL MERITO
   2017F2A2C5_001

   Motor neuron degeneration in Spinal and Bulbar Muscular Atrophy: molecular approaches to counteract mutant androgen receptor neurotoxicity
   FONDAZIONE TELETHON ETS
   GGP14039

   Upregulation of HSPB8 as potential therapeutic approach in familial and sporadic ALS
   ALS_HSPB8
   FONDAZIONE ITALIANA DI RICERCA PER LA SLA - SCLEROSI LATERALE AMIOTROFICA - ARISLA
   ALS_HSPB8

   Dipartimenti di Eccellenza 2018-2022 - Dipartimento di SCIENZE FARMACOLOGICHE E BIOMOLECOLARI
   MINISTERO DELL'ISTRUZIONE E DEL MERITO

   Ruolo protettivo della proteina HSPB8 nelle malattie del motoneurone
   MINISTERO DELLA SALUTE
   02347198
ott-2019
10-lug-2019
Article (author)
File in questo prodotto:
File Dimensione Formato  
Accepted PDF.pdf

Open Access dal 01/11/2020

Descrizione: Accepted manuscript
Tipologia: Post-print, accepted manuscript ecc. (versione accettata dall'editore)
Dimensione 1.59 MB
Formato Adobe PDF
1.59 MB Adobe PDF Visualizza/Apri
1-s2.0-S0197458019301964-main.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 1.53 MB
Formato Adobe PDF
1.53 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/657360
Citazioni
  • ???jsp.display-item.citation.pmc??? 9
  • Scopus 13
  • ???jsp.display-item.citation.isi??? 13
social impact